IL10 and Hepatic fibrosis: DOP reduced LPS entry into the liver to activate the TLR4/NF-κB signaling pathway, thereby reducing the production of inflammatory factors such as TGF-β and TNF-α, increasing the production of anti-inflammatory factors such as IL-10, and reducing the deposition of collagen to treat liver fibrosis (Figure 8).